Deciphering gynaecological pathologies in women with acne and alopecia: an imaging experience

Basharat Mumin, Inzamam Wani, Qazi Shahbaz, Sheikh R Rasool, Irfan Robbani, Mudasir Hamid, Mohd A Ganai

Abstract

Polycystic ovarian syndrome manifests acne and alopecia in teenagers and young adult females. To evaluate ovarian morphology and the prevalence of polycystic ovarian morphology (PCOM) in females between the ages of 21 and 45 who are in the reproductive stage and have isolated acne and/or androgenic alopecia. And their association. The present study was done with patients in the age group of 21 to 45 years with acne and/or androgenic alopecia. Modified Ferriman-Gallwey score was used to assess the degree of hirsutism (with score of more or equal to 8 as significant). Grading of acne vulgaris and androgenic alopecia was done by a single observer. Subjects were then evaluated for biochemical investigations of Hormonal assays on day 2 to 7. Transabdominal ultrasonography was performed in the follicular phase to demonstrate the ovarian morphology. In our study isolated androgenic alopecia was present in 28 patients (24.34%). In our study 54 (46.95%) patients out of 115 had combined acne and androgenic alopecia. In our study out of 33 patients with isolated acne 17 (51.5%) had PCO Morphology with grade I, grade II, grade III having prevalence of 46.2%, 53.8% and 57.1% respectively. In our study of the 28 patients with isolated androgenic alopecia 16 (57.1%) had PCOM with grade I, II and III respectively having prevalence of 56.3%, 55.6%, 66.7% with P value of 0.939. Patients with normal ovarian morphology were 12 in number (42.9%). Of the 54 patients with combined acne and androgenic alopecia 32 (59.3%) had PCOM and 22 patients had normal ovarian morphology. Higher overall prevalence was found in patients with combined acne and alopecia (59.3%) than in isolated groups; acne (51.5%), alopecia (57.1%). In our study it was to found that women with dermatological manifestations like acne and androgenic alopecia with regular menstruation. In our study it was found that these women with have high prevalence of PCOS. (Afr J Reprod Health 2023; 27 [5]: 30-40).

Full Text:

PDF

References

Ndefo UA, Eaton A and Green MR. Polycystic ovary syndrome: a review of treatment options with a focus on pharmacological approaches.

Zawadzki JK and Dunaif A. Diagnostic criteria for polycystic ovary syndrome: towards a rational approach. In Dunaif A, Givens JR, Haseltine FP, editors: Polycystic Ovary Syndrome, Boston, 1992, Blackwell Scientific, p 377.

. Chen X, Yang D, Mo Y, Li L, Chen Y and Huang Y. Prevalence of polycystic ovary syndrome in unselected women from southern China. Eur J Obstet Gynecol Reprod Biol. 2008 Jul;139(1):59-64.

Michelmore KF, Balen AH, Dunger DB and Vessey MP. Polycystic ovaries and associated clinical and biochemical features in young women. Clin Endocrinol (Oxf). 1999 Dec;51(6):779-86

Asunción M, Calvo RM, San Millán JL, Sancho J, Avila S and Escobar-Morreale HF. A prospective study of the prevalence of the polycystic ovary syndrome in unselected Caucasian women from Spain. J Clin Endocrinol Metab.

Azziz R, Woods KS, Reyna R, Key TJ, Knochenhauer ES and Yildiz BO. The prevalence and features of the polycystic ovary syndrome in an unselected population. J Clin Endocrinol Metab.

Diamanti-Kandarakis E, Kouli CR, Bergiele AT, Filandra FA, Tsianateli TC, Spina GG, Zapanti ED and Bartzis MI. A survey of the polycystic ovary syndrome in the Greek island of Lesbos: hormonal and metabolic profile. J Clin Endocrinol Metab

Knochenhauer ES, Key TJ, Kahsar-Miller M, Waggoner W, Boots LR and Azziz R. Prevalence of the polycystic ovary syndrome in unselected black and white women of the southeastern United States: a prospective study. J Clin Endocrinol Metab

Solomon CG. The epidemiology of polycystic ovary syndrome. Prevalence and associated disease risks. Endocrinol Metabol Clin North Am 1999; 28:247

Ibáñez L, Díaz R, López-Bermejo A and Marcos MV. Clinical spectrum of premature pubarche: links to metabolic syndrome and ovarian hyperandrogenism. Rev Endocr Metab Disord. 2009 Mar;10(1):63-76

Rosenfield RL. Clinical review: Identifying children at risk for polycystic ovary syndrome. J Clin Endocrinol Metab 2007; 92:787

Holte J. Disturbances in insulin secretion and sensitivity in women with the polycystic ovary syndrome. Baillieres Clin Endocrinol Metab 1996; 10:221

Trent ME, Rich M, Austin SB and Gordon CM. Quality of life in adolescent girls with polycystic ovary syndrome. Arch Pediatr Adolesc Med. 2002 Jun;156(6):556-60.

Rasgon NL, Rao RC, Hwang S, Altshuler LL, Elman S, Zuckerbrow-Miller J and Korenman SG. Depression in women with polycystic ovary syndrome: clinical and biochemical correlates. J Affect Disord. 2003 May;74(3):299-304.

Norman RJ, Mahabeer S and Masters S. Ethnic differences in insulin and glucose response to glucose between white and Indian women with polycystic ovary syndrome. Fertil Steril 1995; 63:58

Wijeyaratne CN, Balen AH, Barth JH and Belchetz PE. Clinical manifestations and insulin resistance (IR) in polycystic ovary syndrome (PCOS) among South Asians and Caucasians: is there a difference? Clin Endocrinol (Oxf). 2002 Sep;57(3):343-50.

Rotterdam. ESHRE/ASRM-Sponsored PCOS Consensus Workshop Group: Revised 2003 consensus on diagnostic criteria and long-term health risks related

Mumin et al. PCOS in acne and alopecia

African Journal of Reproductive Health May 2023; 27 (5): 38

to polycystic ovary syndrome. Fertil Steril 81:19,2004.

PCOS EPGo. NIH Office of Disease Prevention Evidence-based Methodology Workshop on Polycystic Ovary Syndrome. In: NIH Office of Disease Prevention Methodology Workshops: NIH, 2012.

Azziz R, Carmina E, Dewailly D, Diamanti-Kandarakis E, Escobar-Morreale HF, Futterweit W, Janssen OE, Legro RS, Norman RJ, Taylor AE, Witchel SF and Androgen Excess Society. Positions statement: criteria for defining polycystic ovary syndrome as a predominantly hyperandrogenic syndrome: an Androgen Excess Society guideline. J Clin Endocrinol Metab. 2006 Nov;91(11):4237-45.

Fauser BC, Tarlatzis BC, Rebar RW, Legro RS, Balen AH, Lobo R, Carmina E, Chang J, Yildiz BO, Laven JS, Boivin J, Petraglia F, Wijeyeratne CN, Norman RJ, Dunaif A, Franks S, Wild RA, Dumesic D, and Barnhart K. Consensus on women's health aspects of polycystic ovary syndrome (PCOS): the Amsterdam ESHRE/ASRM-Sponsored 3rd PCOS Consensus Workshop Group. Fertil Steril. 2012 Jan;97(1):28-38. e25

March WA, Moore VM, Willson KJ, Phillips DI, Norman RJ and Davies MJ. The prevalence of polycystic ovary syndrome in a community sample assessed under contrasting diagnostic criteria. Hum Reprod. 2010 Feb;25(2):544-51.

Carmina E and Lobo RA. Am J Polycystic ovaries in Hirsute women with normal menses. Med. 2001 Dec 1; 111(8):602-6

Carmina E and Lobo RA. Do hyperandrogenic women with normal menses have polycystic ovary syndrome? Fertil Steril. 1999 Feb; 71(2):319-22.

Michelmore K, Ong K, Mason S, Bennett S, Perry L, Vessey M, Balen A and Dunger D. Clin Clinical features in women with polycystic ovaries: relationships to insulin sensitivity, insulin gene VNTR and birth weight. Endocrinol (Oxf). 2001 Oct; 55(4):439-46

Norman RJ, Hague WM, Masters SC and Wang XJ Subjects with polycystic ovaries without hyperandrogenaemia exhibit similar disturbances in insulin and lipid profiles as those with polycystic ovary syndrome. Hum Reprod. 1995 Sep; 10(9):2258-61

Nelson VL, Legro RS and Strauss JF. 3rd, McAllister JM. Augmented androgen production is a stable steroidogenic phenotype of propagated theca cells from polycystic ovaries. Mol Endocrinol. 1999 Jun;13(6):946-57.

Nelson VL, Legro RS and Strauss JF. 3rd, McAllister JM. Augmented androgen production is a stable steroidogenic phenotype of propagated theca cells from polycystic ovaries. Mol Endocrinol. 1999 Jun;13(6):946-57.

Eagleson CA, Gingrich MB, Pastor CL, Arora TK, Burt CM, Evans WS and Marshall JC. Polycystic ovarian syndrome: evidence that flutamide restores sensitivity of the gonadotropin-releasing hormone pulse generator to inhibition by estradiol and progesterone. J Clin Endocrinol Metab. 2000 Nov;85(11):4047-52.

Fauser BC, Pache TD, Lamberts SW, Hop WC, de Jong FH and Dahl KD. Serum bioactive and immunoreactive luteinizing hormone and follicle-stimulating hormone levels in women with cycle abnormalities, with or without polycystic ovarian disease. J Clin Endocrinol Metab. 1991 Oct;73(4):811-7.

Taylor AE, McCourt B, Martin KA, Anderson EJ, Adams JM, Schoenfeld D and Hall JE. Determinants of abnormal gonadotropin secretion in clinically defined women with polycystic ovary syndrome. J Clin Endocrinol Metab. 1997 Jul;82(7):2248-56. doi:

Bergh C, Carlsson B, Olsson JH, Selleskog U and Hillensjö T. Regulation of androgen production in cultured human thecal cells by insulin-like growth factor I and insulin. Fertil Steril. 1993 Feb;59(2):323-31.

Rosenfield RL. Clinical practice. Hirsutism N Engl J Med. 2005;353(24):2578–88.

Williamson K, Gunn AJ, Johnson N and Milsom SR. The impact of ethnicity on the presentation of polycystic ovarian syndrome. Aust N Z J Obstet Gynaecol. 2001;41(2):202–6.

Wijeyaratne CN, Balen AH, Barth JH and Belchetz PE. Clinical manifestations and insulin resistance (IR) in polycystic ovary syndrome (PCOS) among South Asians and Caucasians: is there a difference? Clin Endocrinol (Oxf). 2002 Sep;57(3):343-50.

Hatch R, Rosenfield RL, Kim MH and Tredway D. Hirsutism: implications, etiology, and management. Am J Obstet Gynecol. 1981 Aug 1;140(7):815-30.

Chang WY, Knochenhauer ES, Bartolucci AA and Azziz R. Phenotypic spectrum of polycystic ovary syndrome: clinical and biochemical characterization of the three major clinical subgroups. Fertil Steril. 2005 Jun;83(6):1717-23.

Deplewski D and Rosenfield RL. Role of hormones in pilosebaceous unit develop-ment. Endocr Rev 2000; 21 (4): 363-92

Carmina E, Koyama T, Chang L, Stanczyk FZ and Lobo RA. Does ethnicity influence the prevalence of adrenal hyperandrogenism and insulin resistance in polycystic ovary syndrome? Am J Obstet Gynecol. 1992 Dec;167(6):1807-12.

Ehrmann DA and Rosenfield RL. Clinical review 10: an endocrinologic approach to the patient with hirsutism. J Clin Endocrinol Metab 1990; 71 (1): 1-4

Reingold SB and Rosenfield RL. The relationship of mild hirsutism or acne in women to androgens. Arch Dermatol 1987; 123 (2): 209-12

Borgia F, Cannavò S, Guarneri F, Cannavò SP, Vaccaro M and Guarneri B. Correlation between endocrinological parameters and acne severity in adult women. Acta Derm Venereol. 2004;84(3):201-4.

Falsetti L, Gambera A, Andrico S and Sartori E. Acne and hirsutism in polycystic ovary syndrome: clinical, endocrine-metabolic and ultrasonographic differences. Gynecol Endocrinol. 2002 Aug;16(4):275-84.

Aydemir EH. Acne vulgaris. Turk Pediatri Ars. 2014;49(1):13-6.

Zouboulis CC. Acne as a chronic systemic disease. Clin Dermatol. 2014;32(3):389-96.

Ozdemir S, Ozdemir M, Gorkemli H, Kiyici A and Bodur S. Specific dermatologic features of the polycystic ovary syndrome and its association with biochemical markers of the metabolic syndrome and

Mumin et al. PCOS in acne and alopecia

African Journal of Reproductive Health May 2023; 27 (5): 39

hyperandrogenism. Acta Obstet Gynecol Scand. 2010;89(2):199- 204.

Alan S and Cenesizoglu E. Effects of hyperandrogenism and high body mass index on acne severity in women. Saudi Med J. 2014;35(8):886-9.

Burkhart CN and Gottwald L. Assessment of etiologic agents in acne pathogenesis. Skinmed. 2003;2(4):222–8.

Tutakne MA and Chari KVR. Acne, rosacea and perioral dermatitis. In: Valia RG, Valia AR, editors. IADVL Textbook and atlas of dermatology, 2nd ed., Mumbai: Bhalani publishing House; 2003. p. 689-710

Ludwig E. Classification of the types of androgenetic alopecia (common baldness) occurring in the female sex. British Journal of Dermatology 1977 97 247–254.

Hamilton JB. Patterned loss of hair in man: types and incidence. Annals of the New York Academy of Sciences 1951 83 708–718.

Slominski AT, Manna PR and Tuckey RC. On the role of skin in the regulation of local and systemic steroidogenic activities. Steroids. 2015 Nov; 103:72-88.

Smythe CD, Greenall M and Kealey T. The activity of HMG-CoA reductase and acetyl-CoA carboxylase in human apocrine sweat glands, sebaceous glands, and hair follicles is regulated by phosphorylation and by exogenous cholesterol. J Invest Dermatol 1998; 111 (1): 139-48.

Thiboutot D. Acne: hormonal concepts and therapy. Clin Dermatol 2004; 22 (5):419-28.

Choudhry R, Hodgins MB, Van der Kwast TH, Brinkmann AO and Boersma WJ. Localization of androgen receptors in human skin by immunohistochemistry: implications for the hormonal regulation of hair growth, sebaceous glands and sweat glands. J Endocrinol. 1992 Jun;133(3):467-75.

Liang T, Hoyer S, Yu R, Soltani K, Lorincz AL, Hiipakka RA and Liao S. Immunocytochemical localization of androgen receptors in human skin using monoclonal antibodies against the androgen receptor. J Invest Dermatol. 1993 May;100(5):663-6.

Deplewski D and Rosenfield RL. Role of hormones in pilosebaceous unit develop ment. Endocr Rev 2000; 21 (4): 363-92.

Olsen EA. Disorders of hair growth: diagnosis and treatment. 2nd ed. New York: McGraw-Hill Professional, 2003

Guarrera M and Rebora A. Anagen hairs may fail to replace telogen hairs in earlyandrogenetic female alopecia. Dermatology 1996; 192 (1): 28-31.

Courtois M, Loussouarn G, Hourseau C and Grollier JF. Ageing and hair cycles. Br J Dermatol. 1995 Jan;132(1):86-93.

Gollnick H, Cunliffe W, Berson D, Dreno B, Finlay A, Leyden JJ, Shalita AR and Thiboutot D. Global Alliance to Improve Outcomes in Acne. Management of acne: a report from a Global Alliance to Improve Outcomes in Acne. J Am Acad Dermatol. 2003 Jul;49(1 Suppl):S1-37.

Pochi PE and Strauss JS. Endocrinologic control of the development and activity of the human subaceous gland. J Invest Dermatol 1974; 62 (3):191-201

Pochi PE Strauss JS and Downing DT. Age- related changesin subaceous gland activity. J Invest Dermatol 1979; 73 (1); 108-11

Pache TD, Wladimiroff JW, Hop WC and Fauser BC. How to discriminate between normal and polycystic ovaries: transvaginal US study. Radiology 1992;183:421–3.

Van Santbrink EJ, Hop WC and Fauser BC. Classification of normogonadotropic infertility: polycystic ovaries diagnosed by ultrasound versus endocrine characteristics of polycystic ovary syndrome. Fertil Steril 1997;67:452–8.

Jonard S, Robert Y, Cortet-Rudelli C, Pigny P, Decanter C and Dewailly D. Ultrasound examination of polycystic ovaries: is it worth counting the follicles? Hum Reprod 2003;18:598–603.):19–25.

Monash Centre for Health Research and Implementation (MCHRI). Intrnational evidence–based guideline for assessment and management of polycystic ovary syndrome. 2018. Monash.edu/

Jonard S, Robert Y and Dewailly D. Revisiting the ovarian volume as a diagnostic criterion for polycystic ovaries. Hum Reprod 2005;20(10):2893–2898.

Nardo LG, Buckett WM and Khullar V. Determination of the best-fitting ultrasound formulaic method for ovarian volume measurement in women with polycystic ovary syndrome. Fertil Steril 2003;79(3): 632–633

Tony T. Lee MD and Mary E. Rausch, MD, MSCE Polycystic Ovarian Syndrome: Role of Imaging in Diagnosis.2012; 32:1643–1657

Ahmed S, Pahwa S, Das CJ, Mir FA, Nisar S and Jehangir M. Comparative evaluation of sonographic ovarian morphology of Indian women with polycystic ovary syndrome versus those of normal women. Indian J Endocrinol Metab. 2014;18(2):3-8. doi:10.4103/2230-8210.129108

Polson DW, Adams J, Wadsworth J and Franks S. Polycystic ovaries: a common finding in normal women. Lancet 1988;1(8590):870–872.

Lakhani K, Seifalian AM, Atiomo WU and Hardiman P. Polycystic ovaries. Br J Radiol 2002;75(889):9–16.

Scheffer GJ, Broekmans FJ, Dorland M, Habbema JD, Looman CW and te Velde ER. Antral follicle counts by transvaginal ultrasonography are related to age in women with proven natural fertility. Fertil Steril 1999;72(5):845–851.

Adams J, Franks S, Polson DW, Mason HD, Abdulwahid N, Tucker M, Morris DV, Price J and Jacobs HS. Multifollicular ovaries: clinical and endocrine features and response to pulsatile gonadotropin releasing hormone. Lancet. 1985 Dec 21-28;2(8469-70):1375-9.

Buckett WM, Bouzayen R, Watkin KL, Tulandi T and Tan SL. Ovarian stromal echogenicity in women with normal and polycystic ovaries. Hum Reprod 1999;14(3):618–621

Kyei-Mensah AA, LinTan S, Zaidi J and Jacobs HS. Relationship of ovarian stromal volume to serum androgen concentrations in patients with polycystic ovary syndrome. Hum Reprod 1998;13(6): 1437–1441.

Refbacks

  • There are currently no refbacks.